MX2019015707A - Supplement of capsaicin and sulforaphane mixture as anti-inflammatory, anti-fibrotic, and analgesic adjuvant in gastric mucosa inflammation, gastritis induced by different agents. - Google Patents
Supplement of capsaicin and sulforaphane mixture as anti-inflammatory, anti-fibrotic, and analgesic adjuvant in gastric mucosa inflammation, gastritis induced by different agents.Info
- Publication number
- MX2019015707A MX2019015707A MX2019015707A MX2019015707A MX2019015707A MX 2019015707 A MX2019015707 A MX 2019015707A MX 2019015707 A MX2019015707 A MX 2019015707A MX 2019015707 A MX2019015707 A MX 2019015707A MX 2019015707 A MX2019015707 A MX 2019015707A
- Authority
- MX
- Mexico
- Prior art keywords
- inflammatory
- inflammation
- sulforaphane
- capsaicin
- fibrotic
- Prior art date
Links
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 title abstract 4
- SUVMJBTUFCVSAD-UHFFFAOYSA-N sulforaphane Chemical compound CS(=O)CCCCN=C=S SUVMJBTUFCVSAD-UHFFFAOYSA-N 0.000 title abstract 4
- 208000007882 Gastritis Diseases 0.000 title abstract 3
- SUVMJBTUFCVSAD-JTQLQIEISA-N 4-Methylsulfinylbutyl isothiocyanate Natural products C[S@](=O)CCCCN=C=S SUVMJBTUFCVSAD-JTQLQIEISA-N 0.000 title abstract 2
- 239000002671 adjuvant Substances 0.000 title abstract 2
- 230000001760 anti-analgesic effect Effects 0.000 title abstract 2
- 230000003510 anti-fibrotic effect Effects 0.000 title abstract 2
- 230000003110 anti-inflammatory effect Effects 0.000 title abstract 2
- 229960002504 capsaicin Drugs 0.000 title abstract 2
- 235000017663 capsaicin Nutrition 0.000 title abstract 2
- 239000003795 chemical substances by application Substances 0.000 title abstract 2
- 210000001156 gastric mucosa Anatomy 0.000 title abstract 2
- 229960005559 sulforaphane Drugs 0.000 title abstract 2
- 235000015487 sulforaphane Nutrition 0.000 title abstract 2
- 239000013589 supplement Substances 0.000 title abstract 2
- 201000010927 Mucositis Diseases 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 206010061218 Inflammation Diseases 0.000 abstract 2
- 102000004889 Interleukin-6 Human genes 0.000 abstract 2
- 108090001005 Interleukin-6 Proteins 0.000 abstract 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 abstract 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 abstract 2
- 230000004054 inflammatory process Effects 0.000 abstract 2
- 229940100601 interleukin-6 Drugs 0.000 abstract 2
- 102000004127 Cytokines Human genes 0.000 abstract 1
- 108090000695 Cytokines Proteins 0.000 abstract 1
- 241000590002 Helicobacter pylori Species 0.000 abstract 1
- 102000015696 Interleukins Human genes 0.000 abstract 1
- 108010063738 Interleukins Proteins 0.000 abstract 1
- 206010028116 Mucosal inflammation Diseases 0.000 abstract 1
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 abstract 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 abstract 1
- 210000002280 acid secreting cell Anatomy 0.000 abstract 1
- 239000002775 capsule Substances 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 229940037467 helicobacter pylori Drugs 0.000 abstract 1
- 208000013403 hyperactivity Diseases 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 abstract 1
- 230000002018 overexpression Effects 0.000 abstract 1
- 235000013406 prebiotics Nutrition 0.000 abstract 1
- 239000006041 probiotic Substances 0.000 abstract 1
- 235000018291 probiotics Nutrition 0.000 abstract 1
- 239000000047 product Substances 0.000 abstract 1
- 230000000770 proinflammatory effect Effects 0.000 abstract 1
- 210000002784 stomach Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/26—Cyanate or isocyanate esters; Thiocyanate or isothiocyanate esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Botany (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Emergency Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention aims to make available a capsaicin and sulforaphane supplement in combination with prebiotics and probiotics, preferably contained in a capsule for use as an anti-inflammatory, anti-fibrotic, and analgesic adjuvant in mucosal inflammation gastritis induced by different agents. Gastritis is the inflammation of the gastric mucosa, affecting about 50% of the world population and its main etiology is the chronic consumption of non-steroidal anti-inflammatory drugs and infection with Helicobacter pylori, as well as an increase in the activity of acid-secreting cells. Said disease characterizes by the presence of polymorph-nuclear cell infiltrate and overexpression of proinflammatory cytokines, such as tumor necrosis factor-alpha (TNFa), interleukin one beta (IL-1b), interleukin 6 (IL-6), hyperactivity of cyclooxygenase two (COX-2), and its downstream product prostaglandin E2 (PGE2), inducing inflammation in the stomach.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MX2019015707A MX2019015707A (en) | 2019-12-19 | 2019-12-19 | Supplement of capsaicin and sulforaphane mixture as anti-inflammatory, anti-fibrotic, and analgesic adjuvant in gastric mucosa inflammation, gastritis induced by different agents. |
| PCT/MX2020/000051 WO2021125931A1 (en) | 2019-12-19 | 2020-12-11 | Supplement comprising a mixture of capsaicin and sulforaphane as an anti-inflammatory, anti-fibrotic and analgesic coadjuvant for inflammation of the gastric mucosa, gastritis caused by different agents |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MX2019015707A MX2019015707A (en) | 2019-12-19 | 2019-12-19 | Supplement of capsaicin and sulforaphane mixture as anti-inflammatory, anti-fibrotic, and analgesic adjuvant in gastric mucosa inflammation, gastritis induced by different agents. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019015707A true MX2019015707A (en) | 2021-06-21 |
Family
ID=76478458
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019015707A MX2019015707A (en) | 2019-12-19 | 2019-12-19 | Supplement of capsaicin and sulforaphane mixture as anti-inflammatory, anti-fibrotic, and analgesic adjuvant in gastric mucosa inflammation, gastritis induced by different agents. |
Country Status (2)
| Country | Link |
|---|---|
| MX (1) | MX2019015707A (en) |
| WO (1) | WO2021125931A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023021040A1 (en) * | 2021-08-18 | 2023-02-23 | Société des Produits Nestlé S.A. | Mixtures and compositions comprising sulforaphane and glycine |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101068558A (en) * | 2004-08-19 | 2007-11-07 | 普渡研究基金会 | Improved anti-cancer treatment |
| WO2008046140A1 (en) * | 2006-10-17 | 2008-04-24 | Summa Development Limited | Improved treatment for benign prostatic hyperplasia |
| US20120237566A1 (en) * | 2011-03-15 | 2012-09-20 | Venture Isles, LLC | Inhibiting stomach-acid release, reducing inflammation and preventing and treating cancer: compositions and methods of use |
| CN102526360B (en) * | 2011-10-17 | 2014-05-07 | 宁波海逸生物科技有限公司 | Health-care product with weight loss function |
| CN111011856A (en) * | 2019-12-19 | 2020-04-17 | 南京圣诺生物科技实业有限公司 | Composition for relieving gastropathy, preparation method thereof and food for relieving gastropathy |
-
2019
- 2019-12-19 MX MX2019015707A patent/MX2019015707A/en unknown
-
2020
- 2020-12-11 WO PCT/MX2020/000051 patent/WO2021125931A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021125931A1 (en) | 2021-06-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Jiang et al. | Lycopene exerts anti-inflammatory effect to inhibit prostate cancer progression | |
| Takatani et al. | Fucoxanthin inhibits hepatic oxidative stress, inflammation, and fibrosis in diet-induced nonalcoholic steatohepatitis model mice | |
| John et al. | Epithelial barriers in intestinal inflammation | |
| Vane | Aspirin and other anti-inflammatory drugs | |
| Antonisamy et al. | Gastroprotective effect of epoxy clerodane diterpene isolated from Tinospora cordifolia Miers (Guduchi) on indomethacin-induced gastric ulcer in rats | |
| Mazumder et al. | Selective scavenging of intra-mitochondrial superoxide corrects diclofenac-induced mitochondrial dysfunction and gastric injury: A novel gastroprotective mechanism independent of gastric acid suppression | |
| MX2019015707A (en) | Supplement of capsaicin and sulforaphane mixture as anti-inflammatory, anti-fibrotic, and analgesic adjuvant in gastric mucosa inflammation, gastritis induced by different agents. | |
| Alizadeh et al. | A pilot study on controlling coronavirus disease 2019 (COVID-19) inflammation using melatonin supplement | |
| Abbas et al. | Potential benefit of curcumin adjuvant therapy to the standard Helicobacter pylori eradication therapy in patients with peptic ulcer disease | |
| Luo et al. | Low-dose curcumin leads to the inhibition of tumor growth via enhancing CTL-mediated antitumor immunity | |
| Choi et al. | Gastroprotective effects of PMK-S005 against ethanol-induced acute gastric damage in rats | |
| Al Serwi et al. | Growth hormone modulates the inflammatory and apoptotic pathways incorporated in fluorouracil-induced oral mucositis in rats | |
| Jiao et al. | Cyanidin-3-O-galactoside from Aronia melanocarpa attenuates high-fat diet-induced obesity and inflammation via AMPK, STAT3, and NF-κB p65 signaling pathways in Sprague-Dawley rats | |
| Prasad et al. | Capsaicin: a promising multifaceted drug from Capsicum spp. | |
| CN103284988A (en) | Use of propargyl cysteine and analogue thereof in preparation of drug for treating immunity-related inflammation diseases | |
| Song et al. | The metabolic effect of fructose on normal rats in a mild dose with glucose and saccharose as control | |
| Kim et al. | Inhibitory effects of ginger and processed (Beopje) ginger extracts on HCl-ethanol induced gastritis in rats | |
| Li et al. | Anesthetic drug propofol inhibits the expression of interleukin‑6, interleukin‑8 and cyclooxygenase‑2, a potential mechanism for propofol in suppressing tumor development and metastasis | |
| Naeimi et al. | Gastroprotective herbs for headache management in Persian medicine: A comprehensive review | |
| Li et al. | Study on the mechanism of oral administration of tetrandrine during neoadjuvant chemotherapy for colon cancer | |
| EA201592297A1 (en) | AGOMELATIN COMPOSITIONS CONTAINING AGOMELATIN IN THE FORM OF CRYSTALS | |
| MX2022002169A (en) | Compositions and methods using non-steroidal anti-inflammatory drugs. | |
| Choi et al. | PMK-S005 alleviates age-related gastric acid secretion, inflammation, and oxidative status in the rat stomach | |
| Sharifi et al. | The Effect of oral administration pufas on oxidative stress in patients infected by helicobacter pylori with dyspeptic symptom | |
| Sostres et al. | T1961 The Type of NSAID Use and the Characteristics of Patients Who Bleed from the Upper GI Tract Is Different to That Reported in Clinical Trials |